Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bifemelane. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Bifemelane. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Bifemelane. |
| Hydrocodone | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bifemelane. |
| Magnesium sulfate | The therapeutic efficacy of Bifemelane can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Bifemelane may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Bifemelane. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Bifemelane. |
| Orphenadrine | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Bifemelane. |
| Pramipexole | Bifemelane may increase the sedative activities of Pramipexole. |
| Ropinirole | Bifemelane may increase the sedative activities of Ropinirole. |
| Rotigotine | Bifemelane may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Bifemelane. |
| Sodium oxybate | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Bifemelane. |
| Thalidomide | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Bifemelane. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Bifemelane. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Bifemelane is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Bifemelane is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Bifemelane is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Bifemelane is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Bifemelane is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Bifemelane is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Bifemelane is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Bifemelane is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Bifemelane is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Bifemelane is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Bifemelane is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Bifemelane is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Bifemelane is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Bifemelane is combined with (S)-Warfarin. |
| Mirtazapine | Bifemelane may increase the serotonergic activities of Mirtazapine. |
| Ethanol | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Bifemelane may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Bifemelane. |
| Zimelidine | The risk or severity of adverse effects can be increased when Bifemelane is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Bifemelane is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Bifemelane is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Bifemelane is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Bifemelane is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Bifemelane is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Bifemelane is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Bifemelane is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Bifemelane is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Bifemelane is combined with Nefazodone. |
| Milnacipran | The risk or severity of adverse effects can be increased when Bifemelane is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Bifemelane. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Bifemelane is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Bifemelane is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Bifemelane is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Bifemelane is combined with Alaproclate. |
| Methylene blue | Bifemelane may increase the serotonergic activities of Methylene blue. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Bifemelane. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Bifemelane. |
| Zopiclone | The risk or severity of adverse effects can be increased when Bifemelane is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Bifemelane. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Bifemelane. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Bifemelane. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Bifemelane. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Bifemelane. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Bifemelane. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Bifemelane. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Bifemelane. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Bifemelane. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Bifemelane. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Bifemelane. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Bifemelane. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Bifemelane. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Bifemelane. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Bifemelane. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Bifemelane. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Bifemelane. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Bifemelane. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Bifemelane. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Bifemelane. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Bifemelane. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Bifemelane. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Bifemelane. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Bifemelane. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Bifemelane. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Bifemelane. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Bifemelane. |
| Palonosetron | The risk or severity of CNS depression can be increased when Palonosetron is combined with Bifemelane. |
| Dexbrompheniramine | The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Bifemelane. |
| Metocurine iodide | The risk or severity of CNS depression can be increased when Metocurine iodide is combined with Bifemelane. |
| Secobarbital | The risk or severity of CNS depression can be increased when Secobarbital is combined with Bifemelane. |
| Methocarbamol | The risk or severity of CNS depression can be increased when Methocarbamol is combined with Bifemelane. |
| Triprolidine | The risk or severity of CNS depression can be increased when Triprolidine is combined with Bifemelane. |
| Meperidine | The risk or severity of CNS depression can be increased when Meperidine is combined with Bifemelane. |
| Metharbital | The risk or severity of CNS depression can be increased when Metharbital is combined with Bifemelane. |
| Quinine | The risk or severity of CNS depression can be increased when Quinine is combined with Bifemelane. |
| Methohexital | The risk or severity of CNS depression can be increased when Methohexital is combined with Bifemelane. |